ES2525758T3 - Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica - Google Patents

Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica Download PDF

Info

Publication number
ES2525758T3
ES2525758T3 ES11785277.2T ES11785277T ES2525758T3 ES 2525758 T3 ES2525758 T3 ES 2525758T3 ES 11785277 T ES11785277 T ES 11785277T ES 2525758 T3 ES2525758 T3 ES 2525758T3
Authority
ES
Spain
Prior art keywords
peptide
composition
neuraminidase inhibitor
viral neuraminidase
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11785277.2T
Other languages
English (en)
Inventor
Bernhard Fischer
Rudolf Lucas
Hendrik Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeptico Forschung und Entwicklung GmbH
Original Assignee
Apeptico Forschung und Entwicklung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung und Entwicklung GmbH filed Critical Apeptico Forschung und Entwicklung GmbH
Application granted granted Critical
Publication of ES2525758T3 publication Critical patent/ES2525758T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición que comprende - un péptido, que está constituido por 7-17 aminoácidos adyacentes y comprende el hexámero TX1EX2X3E, en el que X1, X2 y X3 pueden ser cualquier aminoácido natural o no natural, no presentando el péptido ninguna actividad de unión al receptor de TNF y estando ciclado, y - un inhibidor de la neuraminidasa vírica.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES11785277.2T 2010-11-18 2011-11-15 Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica Active ES2525758T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1908/2010A AT510585B1 (de) 2010-11-18 2010-11-18 Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
AT19082010 2010-11-18
PCT/AT2011/000462 WO2012065201A1 (de) 2010-11-18 2011-11-15 Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Publications (1)

Publication Number Publication Date
ES2525758T3 true ES2525758T3 (es) 2014-12-30

Family

ID=45001564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11785277.2T Active ES2525758T3 (es) 2010-11-18 2011-11-15 Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica

Country Status (14)

Country Link
US (2) US10344055B2 (es)
EP (1) EP2640410B1 (es)
JP (1) JP5970465B2 (es)
KR (1) KR101872218B1 (es)
CN (2) CN112717122A (es)
AT (1) AT510585B1 (es)
AU (1) AU2011331891A1 (es)
BR (1) BR112013011076A2 (es)
CA (1) CA2817787C (es)
DK (1) DK2640410T3 (es)
ES (1) ES2525758T3 (es)
MX (1) MX2013005391A (es)
RU (1) RU2596785C2 (es)
WO (1) WO2012065201A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
EP2903430A1 (en) * 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
EP2988768B1 (de) * 2013-04-23 2021-03-31 APEPTICO Forschung und Entwicklung GmbH Lyophilisat enthaltend ein zyklisches peptid der formel x1-gqretpegaeakpwy-x2 zur behandlung pulmonarer ödeme
ES2813379T3 (es) * 2013-04-23 2021-03-23 Apeptico Forschung & Entwicklung Gmbh Tratamiento extracorporal del pulmón con un péptido cíclico de formula x1-gqretpegaeakpwy-x2
US20170014472A1 (en) * 2014-03-04 2017-01-19 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
EP3062772B1 (en) * 2014-03-18 2018-01-24 APEPTICO Forschung und Entwicklung GmbH Dry-powder peptide medicament
US20250241978A1 (en) * 2020-05-08 2025-07-31 Apeptico Forschung Und Entwicklung Gmbh Peptide for prevention or treatment of covid-19

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
JPS60243016A (ja) * 1984-05-17 1985-12-03 Tsumura Juntendo Inc 抗インフルエンザウイルス剤
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
AU6001094A (en) * 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
US5958973A (en) 1993-09-03 1999-09-28 Gilead Sciences, Inc. Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors
US5453533A (en) 1994-04-14 1995-09-26 The University Of Alabama At Birmingham Inhibitors of influenza virus neuraminidase and methods of making and using the same
US5512596A (en) 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5866601A (en) 1995-02-27 1999-02-02 Gilead Sciences, Inc. Carbocyclic compounds
CN100409844C (zh) 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US5602277A (en) 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5763483A (en) 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
PL330407A1 (en) 1996-06-14 1999-05-10 Biocryst Pharmaceuticals Substituted cyclopentane compounds useful as neuraminidaze inhibitors
US6451766B1 (en) 1996-07-22 2002-09-17 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US6340702B1 (en) 1996-07-22 2002-01-22 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US5886213A (en) 1997-08-22 1999-03-23 Gilead Sciences, Inc. Preparation of carbocyclic compounds
ZA988469B (en) 1997-09-17 1999-03-17 Biocryst Pharm Inc Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6593314B1 (en) 1999-10-19 2003-07-15 Abbott Laboratories Neuraminidase inhibitors
MXPA03000848A (es) * 2000-07-28 2004-12-13 Immupharm Aps Metodos para el tratamiento de sintomas del resfriado comun, rinitis alergica e infecciones relacionadas con el tracto respiratorio.
WO2003026567A2 (en) * 2001-09-27 2003-04-03 St. Jude Children's Research Hospital, Inc. Use of neuraminidase inhibitors to prevent flu associated bacterial infections
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
EP1781323B1 (en) 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
CA2677905C (en) 2007-02-16 2015-03-24 Toyama Chemical Co., Ltd. Pharmaceutical composition comprising pyrazine derivatives and neuraminidase inhibitors for treating influenza infections
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
CN101487016B (zh) * 2007-09-30 2012-04-18 浙江中奇生物药业股份有限公司 禽流感疫苗及其制备方法
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
JP2010138081A (ja) 2008-12-09 2010-06-24 Kansai Univ インフルエンザウイルス免疫賦活剤、および抗インフルエンザウイルス剤
WO2010099566A1 (en) 2009-03-02 2010-09-10 Manfred Imand Kurmis A sealing member for a closure
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität

Also Published As

Publication number Publication date
CA2817787A1 (en) 2012-05-24
CA2817787C (en) 2019-03-05
RU2013127402A (ru) 2014-12-27
AT510585B1 (de) 2012-05-15
WO2012065201A1 (de) 2012-05-24
CN103200955A (zh) 2013-07-10
AT510585A4 (de) 2012-05-15
US20130261048A1 (en) 2013-10-03
JP5970465B2 (ja) 2016-08-17
US10344055B2 (en) 2019-07-09
DK2640410T3 (da) 2014-11-10
MX2013005391A (es) 2013-07-29
KR101872218B1 (ko) 2018-06-28
US20190309021A1 (en) 2019-10-10
EP2640410B1 (de) 2014-10-29
KR20130139966A (ko) 2013-12-23
AU2011331891A1 (en) 2013-04-11
CN112717122A (zh) 2021-04-30
RU2596785C2 (ru) 2016-09-10
JP2014501718A (ja) 2014-01-23
EP2640410A1 (de) 2013-09-25
BR112013011076A2 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
ES2525758T3 (es) Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2541217T3 (es) Diferenciación de células madre mesenquimales
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
ES2657060T3 (es) Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas
CL2020002010A1 (es) Uso de un polipéptido que comprende una hormona de crecimiento, y ctps adheridos a la misma, para inducir crecimiento o ganancia de peso. (divisional solicitud 201400254)
ES2534744T3 (es) Plasmina modificada de forma recombinante
ES2629749T3 (es) Inmunidad tumoral
ES2650463T3 (es) Tratamiento de enfermedades inflamatorias con ACE2
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
MX2010004298A (es) Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
MX377589B (es) Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
UA118167C2 (uk) Пептид та його застосування
PA8814001A1 (es) Profármacos de péptidos basados en ésteres
DE602005008996D1 (de) Radiofluorierte peptide
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX354302B (es) Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.